切换至 "中华医学电子期刊资源库"

中华针灸电子杂志 ›› 2022, Vol. 11 ›› Issue (04) : 149 -152. doi: 10.3877/cma.j.issn.2095-3240.2022.04.009

综述

基于肠道菌群的中医药干预高血压病研究进展
李甜1, 蔡晓月1, 王娟1, 周巍1, 赵英强1,()   
  1. 1. 300250 天津中医药大学第二附属医院心内科
  • 收稿日期:2022-01-18 出版日期:2022-11-15
  • 通信作者: 赵英强
  • 基金资助:
    天津市卫生计生委中西医结合科研课题(2017145); 天津中医药大学第二附属医院"青苗计划"课题(QMJH202023)

Recent advances in the application of traditional Chinese medicine in hypertension by intervening gut microbiota

Tian Li1, Xiaoyue Cai1, Juan Wang1, Wei Zhou1, Yingqiang Zhao1,()   

  1. 1. Department of Cardiology, the Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
  • Received:2022-01-18 Published:2022-11-15
  • Corresponding author: Yingqiang Zhao
引用本文:

李甜, 蔡晓月, 王娟, 周巍, 赵英强. 基于肠道菌群的中医药干预高血压病研究进展[J/OL]. 中华针灸电子杂志, 2022, 11(04): 149-152.

Tian Li, Xiaoyue Cai, Juan Wang, Wei Zhou, Yingqiang Zhao. Recent advances in the application of traditional Chinese medicine in hypertension by intervening gut microbiota[J/OL]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2022, 11(04): 149-152.

高血压的发病机制尚未完全阐明,近年来研究显示肠道菌群与高血压发生、发展密切相关。该文以肠道菌群为切入点,总结有关中药单体、复方及针灸等通过调控肠道菌群以拮抗高血压及其危险因素的研究,阐述了中医药可能是通过影响某些特定菌种的数量、或提高益生菌丰度、或改变肠道菌群代谢物数量等多种途径干预高血压及并发症,这为中医药防治高血压及危险因素提供更多的理论依据。未来中医药改善肠道微生态失衡可能成为高血压防治的新靶点。

The pathogenesis of hypertension has not been completely revealed. Recent studies have shown that the imbalance of gut microbiota is closely related to the occurrence and development of hypertension. Research progress of Chinese medicine monomers, Chinese medicine compounds and acupuncture in antagonizing hypertension and its risk factors was summarized with a focus on gut microbiota. It is expounded that traditional Chinese medicine(TCM)may treat hypertension and its risk factors by adjusting the abundance of some gut microbiota, improving abundance of probiotics or changing the levels of fermentation metabolites of gut microbiota(short-chain fatty acids, trimethylamine N-oxide, etc.). This provides more theoretical basis for TCM prevention and treatment of hypertension and its risk factors. Adjusting the imbalance of gut microbiota with TCM may be a new way to treat hypertension in the future.

1
Palmu JSalosensaari AHavulinna AS,et al. Association Between the Gut Microbiota and Blood Pressure in a Population Cohort of 6953 Individuals[J]. J Am Heart Assoc20209(15):e016641.
2
Li JZhao FWang Y,et al. Gut microbiotadysbiosis contributes to the development of hypertension[J]. Microbiome20175(1):14 .
3
Yang T, Santisteban MMRodriguez V,et al.Gutdysbiosis is linked to hypertension [J].Hypertension201565(6):1331-1340.
4
Wilck NMatus GMKearney SM,et al. Salt-responsive gut commensal modulates TH17 axis and disease[J].Nature2017551(7682):585-589.
5
Huart JLeenders JTaminiau B,et al. Gutmicrobiota and fecal leves of short-chain fatty acids differ upon 24-hour blood pressure levels in men[J].Hypertension201974(4):1005-1013.
6
Pluznick J.A novel SCFA receptor,themicrobiota,and blood pressure regulation[J].Gut Microbes20145(2):202-207.
7
Robles-VereIToral Mde la Visitación N,et al.Probiotics prevent dysbiosis and the rise in blood pressure in genetic hypertension: role of short-chain fatty acids[J].Mol Nutr Food Res202064(6):el900616.
8
Felizardo RJFde Almeida DCPereira RL,et al.Gut microbial metabolite butyrate protects against proteinuric kidney disease through epigenetic and GPR109a-mediated mechanisms[J].Faseb J201933(11):11894-11908.
9
Wang LZhu QLu AH,et al.Sodium butyrate suppresses angiotensin Ⅱ-induced hypertension by inhibition of renal(pro)renin receptor and intraarenal renin-angiotensin system[J].J Hypertens201735(9):1899-1908.
10
Farhangi MAVajdi M. Gut microbiota-associated trimethylamine N-oxide and increased cardiometabolic risk in adults: a systematic review and dose-response meta-analysis[J].Nutrition Reviews202179(9):1022-1042.
11
申进增,伊琳,杨锐,等.当归油对高血压大鼠肠道菌群多样性影响的16S rDNA技术分析[J].时珍国医国药202031(10):2332-2335.
12
李心芯,闵二虎,王蓓,等.葛根提取物对高盐饮食小鼠血压和肠道菌群的影响[J].营养学报202042(5):491-496,504.
13
李红,谢海彬,齐容,等.车前子粗多糖胶囊调节肠道菌对老年高血压病患者血压影响的临床研究[J].中医临床研究201911(11):15-19.
14
韩聪,姜月华,李伟,等.基于16S rDNA测序技术探索黄芪-丹参药对干预自发性高血压大鼠肠道菌群的机制[J].中华中医药杂志201934(5):2233-2237.
15
亓英姿,姜月华,姜凌宇,等.杜仲-刺蒺藜对老龄自发性高血压大鼠肠道微生物组的影响[J].中华高血压杂志201927(5):454- 462.
16
唐晓婷,熊敏琪,崔金刚,等.清肝益肾祛风复方对高血压肠道菌群失调的干预效应研究[J].现代中西医结合杂志202130(31):3421-3425,3430.
17
甄晓敏,王培伟,崔金刚,等. 清肝益肾祛风方对血管紧张素Ⅱ诱导的高血压小鼠肠道病理及微生态改变的干预研究[J].世界科学技术-中医药现代化202123(12):4686- 4698.
18
吴山永,姜宁华,石彦波,等.小柴胡汤联合厄贝沙坦对高血压患者肠道菌群及脂代谢影响[J].中华中医药学刊202240(1):169-172.
19
徐兴华,俞晓英,金华,等.镇肝熄风汤对自发性高血压大鼠肠黏膜屏障的影响[J].中华中医药杂志202035(6):2808-2812.
20
蔡昀潞,王建波,曲怡,等.基于"肠道菌群-免疫反应"探讨针灸从脾治疗高血压病的作用机制[J].实用中医内科杂志202135(2):84- 87.
21
夏亚玲,刘小阳,杜万红,等.益生菌对动脉粥样硬化患者血清TLR4及LDL-C的影响[J].湖南师范大学学报(医学版)201916(3):41- 44.
22
牟菲.肠道菌群与高脂血症相关性研究[D].中央民族大学,2019.
23
尹胡海.基于16S rDNA分析黄连解毒汤对高脂饲养的SHR肠道菌群的影响[D].广西中医药大学,2020.
24
陈晓君.健脾散精法对2型糖尿病患者血糖控制、肠道菌群及免疫功能的影响[J].新中医202254(9):90- 94.
25
Luo JChai YZhao M,et al. Hypoglycemic effects and modulation of gut microbiota of diabetic mice by saponin from Polygonatu msibiricum[J]. Food Funct202011(5):4327- 4338.
26
Etxeberria UArias NBoqué N,et al.Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats[J].J Nutr Biochem201526(6):651- 660.
27
Xu JLian FZhao L,et al.Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula[J].Isme J20159(3):552-562.
28
Ji WJiang TSun Z,et al.The enhanced pharmacologicaleffects of modified traditional Chinese medicine in attenuationof atherosclerosis is driven by modulation of gut microbiota[J].Front Pharmacol202011:546-589.
[1] 陈嘉婷, 杜美君, 石冰, 黄汉尧. 母体系统性疾病对新生儿唇腭裂发生的影响[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(04): 262-268.
[2] 王浩元, 王舒, 王娟, 杨建军. 基于类器官模型探索肠道与肠道菌群间相互关系的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(03): 220-224.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 刘起帆, 蒋安. 肝硬化门静脉高压症门静脉压力无创测量进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 270-275.
[5] 杨竞, 周光文. 肝硬化门静脉高压症治疗后再出血危险因素分析及预测模型构建[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 296-301.
[6] 刘国龙, 王鹏, 谭超, 杨辉, 彭菊红. 神经外科机器人辅助双通道颅内血肿清除术治疗高血压性脑出血[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 254-256.
[7] 景方坤, 周建波, 王全才, 黄海韬, 李岩峰, 徐杨熙. 神经导航引导下治疗基底节高血压脑出血的短期疗效预测[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 154-159.
[8] 刘微, 张敏, 解美灵, 喻群群, 周娜, 陈光平, 杨祥, 陈亚丽, 刘梅花. 医院-社区一体化模式在高血压患者管理中的应用效果研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(11): 1176-1180.
[9] 张洪, 王宏宇. 神经酰胺与心脏和血管疾病关系的研究进展[J/OL]. 中华临床医师杂志(电子版), 2023, 17(11): 1202-1205.
[10] 王亮, 王君, 吕雪白, 袁玉婷, 刘小慧, 张文超. 抗β1肾上腺素受体自身抗体在高血压并左室舒张功能不全中的临床研究[J/OL]. 中华临床医师杂志(电子版), 2023, 17(10): 1040-1044.
[11] 王金贵. 七秩芳华,针耀未来——天津中医药大学第一附属医院建院70周年[J/OL]. 中华针灸电子杂志, 2024, 13(03): 89-91.
[12] 庞宁东, 蒋贻洲, 姜华, 牛传强, 李海波, 刘浪, 刘珍银, 张靖. 经皮腔内血管成形术治疗儿童肾动脉狭窄的疗效及相关因素分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(01): 22-26.
[13] 王梦卉, 王梦茹, 骆秦, 朱晴, 李南方. 高血压及原发性醛固酮增多症患者血清钾及低钾血症与心电图左心室肥大的关系[J/OL]. 中华诊断学电子杂志, 2024, 12(01): 18-24.
[14] 刘鑫, 裴思雨, 李志强, 陈成文, 傅硕, 卢领, 孙楠楠, 程守全, 谢冰, 张诗文, 王诚. 靶向药物联合缺损修复在成人先天性心脏病相关重度肺动脉高压的应用[J/OL]. 中华心脏与心律电子杂志, 2024, 12(02): 86-93.
[15] 王永彬, 贾彦迅, 尹轶广. 神经导航结合3D重建技术引导神经内镜血肿清除术对高血压脑出血患者的影响[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(02): 153-156.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?